| Interview with Jungeun Kim, PO of Maven VDR Development
| Enhancing Security in Information Asset Exchange with VDR Service
| Optimizing Pharmaceutical and Biotechnology Business with Guidelines
| Opening Growth Opportunities for Domestic Biotechs with KIMCo
Jungeun Kim, Product Owner at JNPMEDI, explains the pharmaceutical and biotechnology-specific virtual data room service 'Maven VDR.'
“The ultimate goal of the Maven VDR service is crystal clear: to facilitate smooth capital raising and appropriate technology exchange for biotechs. Furthermore, we aspire to be a reliable supporter for biotechs as 'experts' throughout the entire clinical trial process of new drug candidates.”
This month, medical data platform company JNPMEDI launched the new 'Maven VDR (Virtual Data Room)' service, which is rare in the domestic market. Jungeun Kim, the Product Owner (PO) of JNPMEDI, who planned and launched this service, was interviewed on the 25th.
Maven VDR can be described as a highly secure 'mailbox' on a network connected to the internet. Users can exchange confidential documents, data, and other internal assets with their counterparts without worrying about leaks or hacking.
PO Kim explained, “Listening to the technology exchange processes of domestic biotechs, it’s common to see new drug candidate materials and technologies, developed with hundreds of billions of won, shared through open cloud services like Google Drive or email services like Outlook. In an era where hacking in open network spaces is becoming more prevalent, I thought a service like Maven VDR was necessary for the safe growth of domestic pharmaceutical and biotech companies.”
From Fundraising to Technology Transactions: The Wide Applications of Maven VDR
Maven VDR, true to its designation as 'pharmaceutical and biotech-specific,' offers services optimized for the pharmaceutical and biotech business. It incorporates guidelines conceptualized from the expertise of JNPMEDI professionals, tailored to situations requiring data exchange in pharmaceutical and biotech business activities.
These guidelines are particularly specialized to provide the necessary documents in the correct format and timing for companies with limited experience in technology transactions, helping them navigate the essential due diligence process efficiently.
PO Kim stated, “Many domestic biotechs struggle with fundraising or technology transactions despite having good materials due to lack of experience. This leads to increased time and costs, often resulting in no outcomes. Using Maven VDR, companies can not only secure a safe VDR but also receive support from JNPMEDI experts, addressing the issue of insufficient insights.”
Additionally, the service allows the free exchange of various file formats suitable for pharmaceutical and biotech businesses without errors.
“While other industries can exchange documents with Word or PDF files, the pharmaceutical and biotech industries require diverse file types due to different analysis data and experimental formats. We plan to continuously update the guidelines to provide specific document formats desired by venture capitalists and big pharma in a timely manner, based on industry trend analysis,” Kim added.
JNPMEDI and KIMCo Collaborate to Lead K-Bio Growth
JNPMEDI, in collaboration with the Korea Innovative Medicines Consortium (KIMCo), is also working to expand fundraising through Maven VDR.
KIMCo is a platform that promotes domestic and global open innovation, pushing for collaborative development and co-investment.
JNPMEDI operates its own investment and technology transaction solution brand, 'JNPMEDI Partners.' Maven VDR is listed as one of the solutions under JNPMEDI Partners.
PO Kim mentioned, “KIMCo opens opportunities for biotechs capable of technology export. By providing solutions combined with IR review information from JNPMEDI Partners, we expect to create opportunities not only for technology export but also for fundraising through overseas venture capital.”
Currently, JNPMEDI is conducting pilot tests for Maven VDR with KIMCo.
Kim concluded, “We are analyzing and researching the services that companies who will actually use the service want. We expect to secure Maven VDR customers directly through KIMCo by next year.”
Source: https://www.dailian.co.kr/news/view/1388355/?sc=Naver
| Interview with Jungeun Kim, PO of Maven VDR Development
| Enhancing Security in Information Asset Exchange with VDR Service
| Optimizing Pharmaceutical and Biotechnology Business with Guidelines
| Opening Growth Opportunities for Domestic Biotechs with KIMCo
Jungeun Kim, Product Owner at JNPMEDI, explains the pharmaceutical and biotechnology-specific virtual data room service 'Maven VDR.'
“The ultimate goal of the Maven VDR service is crystal clear: to facilitate smooth capital raising and appropriate technology exchange for biotechs. Furthermore, we aspire to be a reliable supporter for biotechs as 'experts' throughout the entire clinical trial process of new drug candidates.”
This month, medical data platform company JNPMEDI launched the new 'Maven VDR (Virtual Data Room)' service, which is rare in the domestic market. Jungeun Kim, the Product Owner (PO) of JNPMEDI, who planned and launched this service, was interviewed on the 25th.
Maven VDR can be described as a highly secure 'mailbox' on a network connected to the internet. Users can exchange confidential documents, data, and other internal assets with their counterparts without worrying about leaks or hacking.
PO Kim explained, “Listening to the technology exchange processes of domestic biotechs, it’s common to see new drug candidate materials and technologies, developed with hundreds of billions of won, shared through open cloud services like Google Drive or email services like Outlook. In an era where hacking in open network spaces is becoming more prevalent, I thought a service like Maven VDR was necessary for the safe growth of domestic pharmaceutical and biotech companies.”
From Fundraising to Technology Transactions: The Wide Applications of Maven VDR
Maven VDR, true to its designation as 'pharmaceutical and biotech-specific,' offers services optimized for the pharmaceutical and biotech business. It incorporates guidelines conceptualized from the expertise of JNPMEDI professionals, tailored to situations requiring data exchange in pharmaceutical and biotech business activities.
These guidelines are particularly specialized to provide the necessary documents in the correct format and timing for companies with limited experience in technology transactions, helping them navigate the essential due diligence process efficiently.
PO Kim stated, “Many domestic biotechs struggle with fundraising or technology transactions despite having good materials due to lack of experience. This leads to increased time and costs, often resulting in no outcomes. Using Maven VDR, companies can not only secure a safe VDR but also receive support from JNPMEDI experts, addressing the issue of insufficient insights.”
Additionally, the service allows the free exchange of various file formats suitable for pharmaceutical and biotech businesses without errors.
“While other industries can exchange documents with Word or PDF files, the pharmaceutical and biotech industries require diverse file types due to different analysis data and experimental formats. We plan to continuously update the guidelines to provide specific document formats desired by venture capitalists and big pharma in a timely manner, based on industry trend analysis,” Kim added.
JNPMEDI and KIMCo Collaborate to Lead K-Bio Growth
JNPMEDI, in collaboration with the Korea Innovative Medicines Consortium (KIMCo), is also working to expand fundraising through Maven VDR.
KIMCo is a platform that promotes domestic and global open innovation, pushing for collaborative development and co-investment.
JNPMEDI operates its own investment and technology transaction solution brand, 'JNPMEDI Partners.' Maven VDR is listed as one of the solutions under JNPMEDI Partners.
PO Kim mentioned, “KIMCo opens opportunities for biotechs capable of technology export. By providing solutions combined with IR review information from JNPMEDI Partners, we expect to create opportunities not only for technology export but also for fundraising through overseas venture capital.”
Currently, JNPMEDI is conducting pilot tests for Maven VDR with KIMCo.
Kim concluded, “We are analyzing and researching the services that companies who will actually use the service want. We expect to secure Maven VDR customers directly through KIMCo by next year.”
Source: https://www.dailian.co.kr/news/view/1388355/?sc=Naver